Literature DB >> 35610988

Rapidity of Ozanimod-Induced Symptomatic Response and Remission in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Induction Period of True North.

.   

Abstract

Entities:  

Year:  2022        PMID： 35610988      PMCID： PMC9122069     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  3 in total

1.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.

Authors:  K W Schroeder; W J Tremaine; D M Ilstrup
Journal:  N Engl J Med       Date:  1987-12-24       Impact factor: 91.245

2.  Rapidity of Ozanimod-Induced Symptomatic Response and Remission in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Induction Period of True North.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2022-04

3.  Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.

Authors:  William J Sandborn; Brian G Feagan; Geert D'Haens; Douglas C Wolf; Igor Jovanovic; Stephen B Hanauer; Subrata Ghosh; AnnKatrin Petersen; Steven Y Hua; Ji Hwan Lee; Lorna Charles; Denesh Chitkara; Keith Usiskin; Jean-Frederic Colombel; Loren Laine; Silvio Danese
Journal:  N Engl J Med       Date:  2021-09-30       Impact factor: 176.079
  3 in total
  3 in total

1.  Rapidity of Ozanimod-Induced Symptomatic Response and Remission in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Induction Period of True North.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2022-04

2.  Highlights in Ulcerative Colitis From the 17th Congress of the European Crohn's and Colitis Organisation: Commentary.

Authors:  David T Rubin
Journal:  Gastroenterol Hepatol (N Y)       Date:  2022-04

Review 3.  Ozanimod: A Review in Ulcerative Colitis.

Authors:  Julia Paik
Journal:  Drugs       Date:  2022-08-22       Impact factor: 11.431
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.